📜 What This Document Is 📰

This document is a Form 6-K, which is a report filed with the U.S. Securities and Exchange Commission (SEC) by a foreign private issuer. Simply put, it’s a detailed update designed to keep investors informed about major corporate events or clinical trial results that happen internationally. The filing, dated April 21, 2026, focuses entirely on the positive interim results of a major clinical trial for a drug called Ultomiris.

👉 Why it matters: For investors, this 6-K report signals a potential major breakthrough in the treatment of a rare kidney disease (IgAN), directly impacting the company's future revenue streams and pipeline value.

🏢 What The Company Does 🧑‍🔬

The filing details the corporate structure of AstraZeneca PLC (AZN), a large, global biopharmaceutical company. AstraZeneca focuses its efforts on discovering, developing, and commercializing prescription medicines. Its main therapeutic areas include Oncology, Rare Diseases, and BioPharmaceuticals, plus Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.

A core part of this effort is through Alexion, a specialized division focused on rare and devastating conditions. Alexion is noted for its pioneering work in understanding the complement system—a key component of the body’s immune response.

👉 The Scale: AstraZeneca is a massive global player, with its innovative medicines sold in over 125 countries worldwide. The company is headquartered in Cambridge, UK.

🧬 Understanding IgAN 🦠

This section explains the specific medical condition the drug is targeting: Immunoglobulin A Nephropathy (IgAN). It helps readers understand the severity and rarity of the disease, which is critical context for evaluating the drug's potential impact.

IgAN is a rare, chronic, and inflammatory disease of the kidneys. It starts when the body creates abnormal IgA proteins, which then form immune complexes and deposit in the kidneys. This process activates the complement system, leading to severe damage to the filtering units of the kidney (the glomeruli).

👉 The Risk: The disease progresses slowly, often without symptoms until significant damage has occurred. Up to 560,000 people are diagnosed with IgAN in the US, EU5, and Japan, and for many, the condition poses a high risk of progressing to end-stage kidney disease (ESKD) or kidney failure.

🔬 How Ultomiris Works 🛡️

Ultomiris (ravulizumab) is the drug being tested, and its mechanism of action is crucial to understanding its value. It belongs to a class of drugs called C5 complement inhibitors.

The complement system is part of your body’s immune system, designed to fight infections. However, when it is over-activated—as happens in IgAN—it starts attacking the body's own healthy cells. Ultomiris works by specifically inhibiting the C5 protein in this complement cascade.

👉 The Effect: By inhibiting C5, Ultomiris effectively breaks the damaging cycle of inflammation, giving the kidneys a chance to heal or slow the progressive damage caused by the autoimmune reaction.

🧪 The I CAN Study Design 🔄

The I CAN (ALXN1210-IgAN-320) trial is the large, randomized clinical study testing the drug. Understanding the design is key to trusting the results.

This was a global, Phase III, randomized, double-blind, placebo-controlled trial. This is the gold standard in clinical research, meaning neither the patients nor the doctors knew who was receiving the drug versus the inactive placebo.

• Participants: The study enrolled participants across 28 countries in North America, South America, Europe, Asia, and Australia.
• Treatment Duration: The trial was designed for a total of 106 weeks.
• Randomization: Patients were randomly assigned in a 1:1 ratio to receive either Ultomiris or a placebo.
• Dosage: The drug is administered intravenously. The treatment arm began with a loading dose on Day 1, followed by maintenance dosing every eight weeks.

👉 The Goal: The study was designed to evaluate both the short-term and long-term safety and efficacy of the drug over a protracted 106-week period.

🏆 Interim Analysis Highlights 🌟

The primary purpose of this filing is to report positive findings from a pre-specified interim analysis of the I CAN trial. These results demonstrate that the drug is effective enough to warrant further investigation.

The analysis showed that Ultomiris met its primary endpoint, demonstrating a statistically significant and clinically meaningful reduction of proteinuria at week 34. This primary endpoint was measured by the 24-hour urine protein creatinine ratio (UPCR).

Key Metrics and Findings:

• Proteinuria Reduction: The drug delivered a rapid reduction in proteinuria, observed as early as week 10.
• Primary Endpoint Status: The drug successfully met the primary endpoint of change from baseline in proteinuria (based on 24-hour UPCR) at week 34.
• Other Endpoints: Secondary endpoints also showed positive signs, including a reduction in 24-hour UPCR $\ge$ 50% from baseline at week 34.

👉 Interim vs. Final: While the interim analysis was highly positive, the filing notes that the final primary endpoint—change from baseline in estimated glomerular filtration rate (eGFR)—will not be assessed until week 106.

🗣️ Expert Commentary and Analysis 💬

The success of the drug was highlighted by both the independent investigator and the company's executive leadership, providing confidence in the results.

Clinical Investigator Perspective: Dr. Jonathan Barratt, an investigator and Mayer Professor of Renal Medicine, stated: "The interim I CAN results demonstrate that blocking terminal complement activation, a central driver of kidney inflammation in IgAN, with Ultomiris may play a promising role in reducing proteinuria. We look forward to understanding the full clinical impact of Ultomiris in treating this disease following study completion at two years."

• Why it matters: Commentary from an external academic expert adds significant weight to the data, framing the observed reduction in proteinuria as a potential breakthrough in managing this chronic kidney disease.

Company Leadership Perspective: Marc Dunoyer, CEO of Alexion, AstraZeneca Rare Disease, stated: "These positive data demonstrate that C5 complement inhibition with Ultomiris results in a rapid and clinically meaningful reduction in proteinuria as early as week 10 and underscores its potential as a disease-modifying approach in IgAN."

• Why it matters: This quote emphasizes two points: the speed of the benefit (as early as week 10) and its classification as a "disease-modifying approach"—meaning it may slow or halt the natural progression of the disease, rather than just treating symptoms.

🛡️ Safety Profile and Tolerability ✅

The company dedicated a section to discussing the drug's safety profile. In this report, the observed safety profile was consistent with what was already known about Ultomiris.

• No New Concerns: The filing explicitly states that "no new safety concerns [were] identified" during the trial.
• Overall: This is a positive indicator, suggesting that the drug's therapeutic benefits are achieved without introducing novel or unforeseen risks to the patient population.

🚀 Future Plans and Guidance 📅

The positive interim results trigger several crucial next steps for the company. AstraZeneca is preparing to fast-track the development and approval process for Ultomiris in IgAN.

• Regulatory Filing: The company plans to seek accelerated approval for Ultomiris in key markets.
• Data Presentation: The full results will be presented at a forthcoming medical meeting.
• Trial Continuation: They will continue advancing the I CAN Phase III trial toward its full completion.

👉 The Pathway: The move to seek accelerated approval means the company is highly confident in the data and is preparing to get the drug to patients as quickly as possible, signaling a strong commercial trajectory.

🌐 Global Reach and Business Scope 🌍

The filing provides an overview of the breadth of the parent company, AstraZeneca, and its specialized division, Alexion.

• AstraZeneca: Is a major global science-led biopharmaceutical company that focuses on Oncology, Rare Diseases, and BioPharmaceuticals.
• Alexion: Focuses exclusively on rare diseases and devastating conditions. It is notable for being the first company to translate the complex biology of the complement system into medicines.
• Global Footprint: Alexion, as part of AstraZeneca, is continually expanding its global geographic footprint to serve more rare disease patients worldwide.

🤝 Contacting AstraZeneca 📧

If readers wish to learn more about the company’s finances or corporate activities, the filing provides clear channels for communication.

• For the Investor Relations Team, the filing directs readers to click a specific link.
• For Media contacts, a separate link is provided.

---

🧠 The Analogy 🚤

Think of IgAN as a slowly leaking tire (the kidney). The leak (proteinuria) is ongoing and damages the rim (the glomeruli). The overall complement system is the mechanic who arrives to fix the tear, but in IgAN, the mechanic overreacts, using powerful tools (C5 activation) that end up causing more damage than good. Ultomiris is like a specialized valve that doesn't stop the leak entirely, but it temporarily shuts down the destructive overreaction of the mechanic, giving the tire's rim a crucial window of time to stop deteriorating and stabilize.

🧩 Final Takeaway ✨

The I CAN trial successfully achieved a critical interim milestone, demonstrating that Ultomiris provides rapid and significant protection against IgAN progression by targeting its core inflammatory mechanism. This strong data supports AstraZeneca’s push for accelerated regulatory approval and marks a highly positive development for the rare disease market.